Amicus Therapeutics
AMICUS THERAPEUTICS INC (Form: 10-K/A, Received: 03/03/2017 17:24:08)

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-K/A

 

(Amendment No. 1)

 


 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2016

 

OR

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to           

 

Commission File Number 001-33497

 


 

Amicus Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 


 

Delaware
(State or other jurisdiction of
incorporation or organization)

 

71-0869350
(IRS Employer
Identification No.)

 

1 Cedar Brook Drive, Cranbury, NJ 08512

(Address of principal executive offices)

 

Telephone: (609) 662-2000

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each
class

 

Name of each exchange on which
registered

Common Stock, par value $0.01 per share

 

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 


 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  x   No  o

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes  o    No  x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x   No  o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  x   No  o

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§22.405) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  x

Accelerated filer  o

Non-accelerated filer  o
(Do not check if a smaller reporting company)

Smaller Reporting Company o

 

Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  o   No  x

 

The aggregate market value of the 99,320,855 shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as reported on The NASDAQ Global Market, as of the last business day of the registrant’s most recently completed second fiscal quarter (June 30, 2016) was approximately $ 542,291,868 . Shares of voting and non-voting stock held by executive officers, directors and holders of more than 10% of the outstanding stock have been excluded from this calculation because such persons or institutions may be deemed affiliates. This determination of affiliate status is not a conclusive determination for other purposes.

 

As of February 15, 2017, there were 142,741,036 shares of common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Proxy Statement for the registrant’s 2016 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.

 

 

 



 

EXPLANATORY NOTE

 

Amicus Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (“Amendment No. 1”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was originally filed with the Securities and Exchange Commission (“SEC”) on March 1, 2017 (the “Original Annual Report”), for the sole purpose of correcting the number of shares of common stock outstanding as of February 15, 2017 which was reported on the cover page of the Original Annual Report.

 

This Amendment No. 1 on Form 10-K/A continues to speak as of the date of the filing of the Original Annual Report, and the Company has not changed the financial statements nor updated the disclosures contained therein to reflect any events that occurred at a later date.

 

2



 

PART IV

 

Item 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULE

 

(a)                                  1. Consolidated Financial Statements

 

The Consolidated Financial Statements are filed as part of this report.

 

2.      Consolidated Financial Statement Schedules

 

All schedules are omitted because they are not required or because the required information is included in the Consolidated Financial Statements or notes thereto.

 

3.      Exhibits The exhibits listed in the accompanying Exhibit Index are filed as part of this Amendment No. 1 to Annual Report on Form 10-K.

 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

2.1

 

Agreement and Plan of Merger, dated November 19, 2013, by and among Amicus Therapeutics, Inc., CB Acquisition Corp., Callidus BioPharma, Inc., and Cuong Do

 

Form 8-K

 

2/12/2014

 

2.1

 

 

+2.2

 

Agreement and Plan of Merger, dated August 30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm, Inc.

 

Form 8-K

 

9/3/15

 

2.1

 

 

2.3

 

Amendment to Agreement and Plan of Merger, dated September 30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm, Inc.

 

Form 8-K

 

9/30/15

 

2.2

 

 

+2.4

 

Agreement and Plan of Merger, dated July 5, 2016, by and among MiaMed, Inc., the Registrant and Minervas Merger Sub, Inc.

 

Form 8-K

 

7/6/16

 

2.1

 

 

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Restated Certificate of Incorporation of the Registrant.

 

Form 10-K

 

2/28/12

 

3.1

 

 

3.2

 

Restated By-laws of the Registrant.

 

S-1/A (333-141700)

 

4/27/07

 

3.4

 

 

3.3

 

Certificate of Amendment to the Registrant’s Restated Certificate of Incorporation, as amended.

 

Form 8-K

 

6/10/2015

 

3.1

 

 

 

3



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

4.1

 

Specimen Stock Certificate evidencing shares of common stock

 

S-1 (333-141700)

 

3/30/07

 

4.1

 

 

4.2

 

Third Amended and Restated Investor Rights Agreement, dated as of September 13, 2006, as amended

 

S-1 (333-141700)

 

3/30/07

 

4.3

 

 

4.3

 

Form of Warrant issued on November 20, 2013

 

Form 8-K

 

11/21/13

 

10.2

 

 

4.4

 

Form of Warrant, issued on October 1, 2015

 

Form 8-K

 

10/1/15

 

4.1

 

 

4.5

 

Form of Warrant to Purchase Common Stock

 

Form 8-K

 

2/22/16

 

4.1

 

 

4.6

 

Form of Warrant to Purchase Common Stock

 

Form 8-K

 

7/1/16

 

4.1

 

 

4.7

 

Form of Indenture

 

Form S-3ASR

 

4/29/16

 

4.7

 

 

4.8

 

Indenture, dated December 21, 2016, by and between the Registrant and Wilmington Trust, National Association

 

Form 8-K

 

12/21/16

 

4.1

 

 

*10.1

 

2002 Equity Incentive Plan, as amended, and forms of option agreements thereunder

 

S-1/A (333-141700)

 

4/27/07

 

10.1

 

 

+10.2

 

Amended and Restated License Agreement, dated October, 31, 2008, by and between the Registrant and Mount Sinai School of Medicine of New York University

 

Form 10-K

 

2/6/09

 

10.3

 

 

+10.3

 

License Agreement, dated as of June 26, 2003, by and between the Registrant and University of Maryland, Baltimore County, as amended

 

S-1 (333-141700)

 

3/30/07

 

10.4

 

 

+10.4

 

Exclusive License Agreement, dated as of June 8, 2005, by and between the Registrant and Novo Nordisk, A/S

 

S-1 (333-141700)

 

3/30/07

 

10.5

 

 

*10.5

 

Letter Agreement, dated as of December 19, 2005, by and between the Registrant and David Lockhart, Ph.D.

 

S-1 (333-141700)

 

3/30/07

 

10.10

 

 

10.6

 

Form of Director and Officer Indemnification Agreement

 

S-1 (333-141700)

 

3/30/07

 

10.17

 

 

 

4



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

*10.7

 

Amended and Restated 2007 Director Option Plan and form of option agreement

 

Form 8-K

 

6/18/10

 

10.2

 

 

*10.8

 

2007 Employee Stock Purchase Plan

 

S-1/A (333-141700)

 

5/17/07

 

10.24

 

 

*10.11

 

Management Bonus Program Summary

 

Form 8-K

 

6/9/16

 

10.1

 

 

*10.12

 

Letter Agreement, dated as of May 10, 2010 by and between the Registrant and Ken Valenzano

 

Form 10-K

 

3/4/11

 

10.32

 

 

*10.14

 

Letter Agreement, dated as of January 3, 2011 by and between the Registrant and Enrique Dilone

 

Form 10-K

 

3/4/11

 

10.34

 

 

10.15

 

Lease Agreement dated August 16, 2011 between the Registrant and Cedar Brook 3 Corporate Center, L.P.

 

Form 8-K

 

8/16/11

 

10.1

 

 

10.17

 

Second Amendment to Lease Agreement dated as of May 16, 2013 by and between the Registrant and A/G Touchstone, TP, LLC.

 

Form 8-K

 

5/22/13

 

10.1

 

 

*10.18

 

Letter Agreement, dated as of June 5, 2013 by and between the Registrant and Jeffrey P. Castelli

 

Form 10-Q

 

8/7/13

 

10.6

 

 

*10.19

 

Letter Agreement, dated as of June 5, 2013 by and between the Registrant and Jayne Gershkowitz

 

Form 10-Q

 

8/7/13

 

10.7

 

 

10.20

 

Securities Purchase Agreement, dated November 20, 2013 by and among the Company and the purchasers identified therein

 

Form 8-K

 

11/20/13

 

10.1

 

 

10.21

 

Credit and Security Agreement, by and between MidCap Funding III, LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma, Inc., dated as of December 27, 2013

 

Form 8-K

 

12/30/13

 

10.1

 

 

 

5



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

+10.23

 

Second Restated Agreement, dated November 19, 2013 by and between the Registrant and Glaxo Group Limited

 

Form 10-K

 

3/3/14

 

10.46

 

 

*10.24

 

Amicus Therapeutics, Inc. Cash Deferral Plan

 

Form 8-K

 

7/2/14

 

10.1

 

 

10.25

 

Amendment No.1 to the Amicus Therapeutics, Inc. Cash Deferral Plan

 

Form 8-K

 

10/16/14

 

10.1

 

 

*10.26

 

Employment Agreement dated April 23, 2014, between the Registrant and John F. Crowley

 

Form 8-K

 

4/25/14

 

10.1

 

 

*10.27

 

Employment Agreement dated April 23, 2014, between the Registrant and William D. Baird, III

 

Form 8-K

 

4/25/14

 

10.2

 

 

*10.28

 

Employment Agreement dated April 23, 2014, between the Registrant and Bradley L. Campbell

 

Form 8-K

 

4/25/14

 

10.3

 

 

*10.29

 

Employment Agreement dated April 23, 2014, between the Registrant and Jay Barth, M.D.

 

Form 10-Q

 

5/5/14

 

10.6

 

 

*10.30

 

Letter Agreement dated April 24, 2014, between the Registrant and Julie Yu

 

Form 10-Q

 

5/5/14

 

10.7

 

 

*10.31

 

Letter Agreement dated April 30, 2014, between the Registrant and Daphne Quimi

 

Form 10-Q

 

5/5/14

 

10.8

 

 

*10.32

 

Amended and Restated 2007 Equity Incentive Plan

 

Form 8-K

 

6/13/16

 

10.1

 

 

*10.33

 

Amicus Therapeutics, Inc. Cash Deferral Plan

 

Form 8-K

 

10/28/16

 

10.1

 

 

*10.34

 

Employment Agreement dated December 17, 2015 between the Registrant and Hung Do

 

Form 10-K

 

2/29/16

 

10.37

 

 

*10.35

 

Employment Agreement dated December 17, 2015 between the Registrant and Dipal Doshi

 

Form 10-K

 

2/29/16

 

10.38

 

 

*10.36

 

Amendment No. 1 to the Amicus Therapeutics, Inc. Cash Deferral Plan

 

Form 8-K

 

10/16/14

 

10.1

 

 

 

6



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

10.37

 

First Amendment to Credit and Security Agreement by and between MidCap Funding III, LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma, Inc., dated as of April 27, 2015.

 

Form 8-K

 

4/28/15

 

10.1

 

 

10.38

 

Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated October 1, 2015

 

Form 8-K

 

10/1/15

 

10.1

 

 

10.39

 

First Amendment to Lease, dated September 9, 2015, by and between Cedar Brook 3 Corporate Center, L.P. and the Registrant

 

Form 8-K

 

9/14/15

 

10.1

 

 

10.40

 

Sales Agreement, dated February 26, 2016, by and between the Registrant and Cowen and Company, LLC

 

Form 8-K

 

2/26/16

 

10.1

 

 

*10.41

 

Retention Bonus Letter, dated March 10, 2016, by and between the Registrant and Jay Barth, M.D.

 

Form 8-K

 

3/15/16

 

10.1

 

 

10.42

 

Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated February 19, 2016.

 

Form 8-K

 

2/22/16

 

10.1

 

 

 

7



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

10.43

 

Joinder to and Amendment of Note and Warrant Purchase Agreement by and among Amicus Therapeutics, Inc., Amicus Therapeutics UK Limited, Amicus Therapeutics International Holding LTD and the purchasers identified on the signature pages thereto, dated as of June 30, 2016

 

Form 8-K

 

7/1/16

 

10.1

 

 

*10.44

 

Amendment No. 1 to the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan

 

Form 8-K

 

7/29/16

 

10.1

 

 

*10.45

 

Secondment Letter, dated August 22, 2016 by and between the Registrant and Bradley Campbell

 

Form 8-K

 

8/23/16

 

10.1

 

 

10.46

 

Base Capped Call Transaction, dated December 15, 2016, by and between the Registrant and Goldman, Sachs & Co.

 

Form 8-K

 

12/21/16

 

10.1

 

 

10.47

 

Base Capped Call Transaction, dated December 15, 2016, by and between the Registrant and JPMorgan Chase Bank, National Association

 

Form 8-K

 

12/21/16

 

10.2

 

 

10.48

 

Base Capped Call Transaction, dated December 15, 2016, by and between the Registrant and Royal Bank of Canada

 

Form 8-K

 

12/21/16

 

10.3

 

 

10.49

 

Additional Capped Call Transaction, dated December 19, 2016, by and between the Registrant and Goldman, Sachs & Co.

 

Form 8-K

 

12/21/16

 

10.4

 

 

10.50

 

Additional Capped Call Transaction, dated December 19, 2016, by and between the Registrant and JPMorgan Chase Bank, National Association

 

Form 8-K

 

12/21/16

 

10.5

 

 

 

8



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

10.51

 

Additional Capped Call Transaction, dated December 19, 2016, by and between the Registrant and Royal Bank of Canada

 

Form 8-K

 

12/21/16

 

10.6

 

 

10.52

 

Note Purchase Agreement, dated December 15, 2016, by and among the Registrant, Amicus Therapeutics International Holding LTD and P Redmile Ltd.

 

Form 8-K

 

12/21/16

 

10.7

 

 

10.53

 

Note Purchase Agreement, dated December 15, 2016, by and among the Registrant, Amicus Therapeutics International Holding LTD and Redmile Capital Offshore Fund, Ltd.

 

Form 8-K

 

12/21/16

 

10.8

 

 

10.54

 

Note Purchase Agreement, dated December 15, 2016, by among the Registrant, Amicus Therapeutics International Holding LTD and Redmile Capital Offshore Fund II, Ltd.

 

Form 8-K

 

12/21/16

 

10.9

 

 

10.55

 

Note Purchase Agreement, dated December 15, 2016, by and among the Registrant, Amicus Therapeutics International Holding LTD and Redmile Special Opportunities Fund, Ltd.

 

Form 8-K

 

12/21/16

 

10.10

 

 

10.56

 

Note Purchase Agreement, dated December 15, 2016, by and among the Registrant, Amicus Therapeutics International Holding LTD and Redmile Capital Fund, LP

 

Form 8-K

 

12/21/16

 

10.11

 

 

10.57

 

Note Purchase Agreement, dated December 15, 2016, by and between Amicus Therapeutics International Holding LTD and GCM Grosvenor Special Opportunities Master Fund, Ltd.

 

Form 8-K

 

12/21/16

 

10.12

 

 

 

9



 

Exhibit

 

 

 

 

 

Incorporated by Reference to SEC Filing

 

Filed with
this

No.

 

Filed Exhibit Description

 

Form

 

Date

 

Exhibit No.

 

Form 10-K

*10.58

 

Form of Performance-Based Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan

 

Form 8-K

 

12/30/16

 

10.1

 

 

21

 

List of Subsidiaries

 

Form 10-K

 

3/1/17

 

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm.

 

Form 10-K

 

3/1/17

 

 

 

 

31.1

 

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

 

 

 

 

 

 

 

X

31.2

 

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

 

 

 

 

 

 

 

X

32.1

 

Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

32.2

 

Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

101

 

The following financial information from this Annual Report on Form 10-K for the year ended December 31, 2016, formatted in XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) the Consolidated Statements of Comprehensive Loss; (iv) the Consolidated Statements of Cash Flows; (v) and the Notes to the Consolidated Financial Statements.

 

Form 10-K

 

 

 

 

 

X

 


+                                          Confidential treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange Commission.

 

*                                          Indicates management contract or compensatory plan.

 

10



 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

AMICUS THERAPEUTICS, INC.

 

 

 

Date: March 3, 2017

By:

/s/ John F. Crowley

 

 

John F. Crowley

 

 

Chairman and Chief Executive Officer

 

 

(Principal Executive Officer)

 

11



 

Exhibit Index

 

Exhibit

 

 

No.

 

Exhibit Description

31.1

 

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2

 

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1

 

Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

 

Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley Act of 2002.

 

12


EXHIBIT 31.1

 

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER

 

I, John F. Crowley, certify that:

 

1. I have reviewed this annual report on Form 10-K, as amended by Amendment No.1 to Annual Report on Form 10-K of Amicus Therapeutics, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this  report is being prepared;

 

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 3, 2017

 

/s/ John F. Crowley

 

John F. Crowley

 

Chairman and Chief Executive Officer

 

 


 

EXHIBIT 31.2

 

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER

 

I, William D. Baird III, certify that:

 

1. I have reviewed this annual report on Form 10-K, as amended by Amendment No.1 to Annual Report on Form 10-K of Amicus Therapeutics, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 3, 2017

 

/s/ William D. Baird III 

 

William D. Baird III

 

Chief Financial Officer

 

 


EXHIBIT 32.1

 

Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section 1350, as

Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U. S. C. Section 1350, I, John F. Crowley, hereby certify that, to the best of my knowledge, Amicus Therapeutics Inc., (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2016 (the “Report”), as filed with the Securities and Exchange Commission on March 1, 2017, as amended by Amendment No. 1 to Annual Report on Form 10-K for the year ended December 31, 2016 filed on March 3, 2017, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ John F. Crowley

 

John F. Crowley

 

Chairman and Chief Executive Officer

 

March 3, 2017

 

 


EXHIBIT 32.2

 

Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section 1350, as

Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U. S. C. Section 1350, I, William D. Baird III, hereby certify that, to the best of my knowledge, the Amicus Therapeutics Inc. (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2016 (the “Report”), as filed with the Securities and Exchange Commission on March 1, 2017, as amended by Amendment No. 1 to Annual Report on Form 10-K for the year ended December 31, 2016 filed on March 3, 2017, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ William D. Baird III

 

William D. Baird III

 

Chief Financial Officer

 

March 3, 2017